Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study

M. Dreyling, A. Santoro, L. Mollica, S. Leppa, G. A. Follows, G. Lenz, W. S. Kim, A. Nagler, P. Panayiotidis, J. Demeter, M. Ozcan, M. Kosinova, K. Bouabdallah, F. Morschhauser, D. A. Stevens, D. Trevarthen, M. Giurescu, L. Kupit, B. H. Childs, P. L. Zinzani

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Original languageEnglish
JournalOncology research and treatment
Volume40
Pages (from-to)12-12
Number of pages1
ISSN2296-5270
Publication statusPublished - Sep 2017

Cite this

Dreyling, M. ; Santoro, A. ; Mollica, L. ; Leppa, S. ; Follows, G. A. ; Lenz, G. ; Kim, W. S. ; Nagler, A. ; Panayiotidis, P. ; Demeter, J. ; Ozcan, M. ; Kosinova, M. ; Bouabdallah, K. ; Morschhauser, F. ; Stevens, D. A. ; Trevarthen, D. ; Giurescu, M. ; Kupit, L. ; Childs, B. H. ; Zinzani, P. L. / Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma : primary results of the pivotal Chronos-1 study. In: Oncology research and treatment. 2017 ; Vol. 40. pp. 12-12.
@article{64ac31971ed94c11a93411eece7e4cba,
title = "Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study",
author = "M. Dreyling and A. Santoro and L. Mollica and S. Leppa and Follows, {G. A.} and G. Lenz and Kim, {W. S.} and A. Nagler and P. Panayiotidis and J. Demeter and M. Ozcan and M. Kosinova and K. Bouabdallah and F. Morschhauser and Stevens, {D. A.} and D. Trevarthen and M. Giurescu and L. Kupit and Childs, {B. H.} and Zinzani, {P. L.}",
year = "2017",
month = "9",
language = "English",
volume = "40",
pages = "12--12",
journal = "Oncology research and treatment",
issn = "2296-5270",
publisher = "Karger",

}

Dreyling, M, Santoro, A, Mollica, L, Leppa, S, Follows, GA, Lenz, G, Kim, WS, Nagler, A, Panayiotidis, P, Demeter, J, Ozcan, M, Kosinova, M, Bouabdallah, K, Morschhauser, F, Stevens, DA, Trevarthen, D, Giurescu, M, Kupit, L, Childs, BH & Zinzani, PL 2017, 'Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal Chronos-1 study' Oncology research and treatment, vol. 40, pp. 12-12.

Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma : primary results of the pivotal Chronos-1 study. / Dreyling, M.; Santoro, A.; Mollica, L.; Leppa, S.; Follows, G. A.; Lenz, G.; Kim, W. S.; Nagler, A.; Panayiotidis, P.; Demeter, J.; Ozcan, M.; Kosinova, M.; Bouabdallah, K.; Morschhauser, F.; Stevens, D. A.; Trevarthen, D.; Giurescu, M.; Kupit, L.; Childs, B. H.; Zinzani, P. L.

In: Oncology research and treatment, Vol. 40, 09.2017, p. 12-12.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - Copanlisib (COP) in patients with relapsed or refractory indolent B-cell lymphoma

T2 - primary results of the pivotal Chronos-1 study

AU - Dreyling, M.

AU - Santoro, A.

AU - Mollica, L.

AU - Leppa, S.

AU - Follows, G. A.

AU - Lenz, G.

AU - Kim, W. S.

AU - Nagler, A.

AU - Panayiotidis, P.

AU - Demeter, J.

AU - Ozcan, M.

AU - Kosinova, M.

AU - Bouabdallah, K.

AU - Morschhauser, F.

AU - Stevens, D. A.

AU - Trevarthen, D.

AU - Giurescu, M.

AU - Kupit, L.

AU - Childs, B. H.

AU - Zinzani, P. L.

PY - 2017/9

Y1 - 2017/9

M3 - Meeting Abstract

VL - 40

SP - 12

EP - 12

JO - Oncology research and treatment

JF - Oncology research and treatment

SN - 2296-5270

ER -